Rock Creek Pharmaceuticals, Inc. (RCPIQ) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Sarasota, FL, 미국. 현재 CEO는 Michael John Mullan MBBS (M.D.,),.
RCPIQ 을(를) 보유 IPO 날짜 1998-02-27, 5 명의 정규직 직원, 에 상장 Other OTC.
Rock Creek Pharmaceuticals, Inc., a pharmaceutical development company, focuses on the discovery, development, and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its lead compound is Anatabine citrate, a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics, with a mechanism of action distinct from other anti-inflammatory drugs available, such as biologics, steroids, and non-steroidal anti-inflammatories. The company was formerly known as Star Scientific, Inc. and changed its name to Rock Creek Pharmaceuticals, Inc. in June 2014. Rock Creek Pharmaceuticals, Inc. is headquartered in Sarasota, Florida. On September 27, 2016, Rock Creek Pharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Delaware.
